Nifedipine blockade of ergonovine-induced coronary arterial spasm: angiographic documentation.
To determine whether calcium-flux blockade with nifedipine blunts coronary vasospasm, four patients with angiographically demonstrable coronary arterial spasm in the absence of significant fixed coronary arterial stenosis were evaluated with coronary arteriography before and after treatment with nifedipine. After initial coronary arteriography, ergonovine was administered in successive doses of 0.05, 0.1 and (when necessary) 0.2 mg intravenously at 3 minute intervals. Three patients had symptomatic high grade focal coronary arterial spasm with electrocardiographic changes, and the fourth exhibited asymptomatic 60 percent constriction of the left anterior descending coronary artery. A maximal ergonovine challenge was repeated 30 minutes later after each patient had been pretreated with a 20 mg sublingual dose of nifedipine. Under these conditions, no patient had chest pain or electrocardiographic changes. Furthermore, neither focal nor diffuse coronary arterial spasm was demonstrable angiographically after the second challenge. Thus, in each case, a single dose of nifedipine precluded the angiographic expression of ergonovine-provoked coronary arterial spasm.
D000787:Angina Pectoris / Q000209:etiology*; D000788:Angina Pectoris, Variant / Q000209:etiology*; D017023:Coronary Angiography; D004562:Electrocardiography; D004874:Ergonovine / Q000494:pharmacology*; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000494:pharmacology*; D010146:Pain / Q000209:etiology; D011725:Pyridines / Q000494:pharmacology*; D013909:Thorax / Q000503:physiopathology
D011725:Pyridines; D009543:Nifedipine; D004874:Ergonovine